DE60011771T2 - Formulierung enthaltend testosteonundecanoat und rizinusöl - Google Patents

Formulierung enthaltend testosteonundecanoat und rizinusöl Download PDF

Info

Publication number
DE60011771T2
DE60011771T2 DE60011771T DE60011771T DE60011771T2 DE 60011771 T2 DE60011771 T2 DE 60011771T2 DE 60011771 T DE60011771 T DE 60011771T DE 60011771 T DE60011771 T DE 60011771T DE 60011771 T2 DE60011771 T2 DE 60011771T2
Authority
DE
Germany
Prior art keywords
liquid carrier
castor oil
pharmaceutical formulation
testosterone undecanoate
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60011771T
Other languages
German (de)
English (en)
Other versions
DE60011771D1 (de
Inventor
Henrik Nijs De
Susan Marlsborough CHANDLER
Anne Elizabeth Swindon PERRY
Josephine Joan Christine Monkton Park FERDINANDO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of DE60011771D1 publication Critical patent/DE60011771D1/de
Publication of DE60011771T2 publication Critical patent/DE60011771T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
DE60011771T 1999-04-01 2000-03-27 Formulierung enthaltend testosteonundecanoat und rizinusöl Expired - Lifetime DE60011771T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99302581 1999-04-01
EP99302581 1999-04-01
PCT/EP2000/002677 WO2000059512A1 (en) 1999-04-01 2000-03-27 Formulation comprising testosteron undecanoate and castor oil

Publications (2)

Publication Number Publication Date
DE60011771D1 DE60011771D1 (de) 2004-07-29
DE60011771T2 true DE60011771T2 (de) 2004-11-04

Family

ID=8241306

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60011771T Expired - Lifetime DE60011771T2 (de) 1999-04-01 2000-03-27 Formulierung enthaltend testosteonundecanoat und rizinusöl

Country Status (26)

Country Link
EP (1) EP1189620B1 (https=)
JP (1) JP2002541111A (https=)
KR (1) KR100666016B1 (https=)
CN (1) CN1155385C (https=)
AT (1) ATE269708T1 (https=)
AU (1) AU768537B2 (https=)
BR (1) BR0009465A (https=)
CA (1) CA2366856C (https=)
CZ (1) CZ298573B6 (https=)
DE (1) DE60011771T2 (https=)
DK (1) DK1189620T3 (https=)
ES (1) ES2222199T3 (https=)
HU (1) HU229455B1 (https=)
ID (1) ID30481A (https=)
IL (2) IL145524A0 (https=)
MX (1) MXPA01009919A (https=)
NO (1) NO329420B1 (https=)
NZ (1) NZ514290A (https=)
PL (1) PL195163B1 (https=)
PT (1) PT1189620E (https=)
RU (1) RU2246296C2 (https=)
SK (1) SK286071B6 (https=)
TR (1) TR200102769T2 (https=)
TW (1) TWI280124B (https=)
WO (1) WO2000059512A1 (https=)
ZA (1) ZA200107781B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
JO2505B1 (en) 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
ATE319426T1 (de) 2003-11-11 2006-03-15 Mattern Udo Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
US20060140820A1 (en) 2004-12-28 2006-06-29 Udo Mattern Use of a container of an inorganic additive containing plastic material
CA2604943C (en) * 2005-04-15 2013-09-17 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
WO2008040488A1 (en) 2006-10-04 2008-04-10 M & P Patent Aktiengesellschaft Controlled release delivery system for nasal application of neurotransmitters
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
AU2010351080B2 (en) * 2010-04-12 2014-08-28 Besins Healthcare Luxembourg S.A.R.L. Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
UA114705C2 (uk) * 2011-01-26 2017-07-25 Аллерган, Інк. Андрогенна композиція для лікування офтальмологічного захворювання
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
AU2015276321B2 (en) 2014-06-17 2019-10-24 Merck Sharp & Dohme B.V. Stable formulations of testosterone undecanoate
SG11201609352TA (en) * 2014-06-19 2017-01-27 Solural Pharma ApS Solid oral dosage form of lipophilic compounds
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033611A1 (en) * 2014-08-29 2016-03-03 Lipocine Inc. (17-β)-3-OXOANDROST-4-EN-17-YL UNDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
AU2019308326B2 (en) * 2018-07-20 2025-07-31 Lipocine Inc. Liver disease
US11564933B2 (en) 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1102095A (zh) * 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9415810D0 (en) * 1994-08-04 1994-09-28 Jerrow Mohammad A Z Composition
GB9608719D0 (en) * 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (sv) * 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet

Also Published As

Publication number Publication date
ES2222199T3 (es) 2005-02-01
IL145524A0 (en) 2002-06-30
CN1346274A (zh) 2002-04-24
NO20014718D0 (no) 2001-09-28
HUP0200453A2 (hu) 2002-07-29
HUP0200453A3 (en) 2003-06-30
BR0009465A (pt) 2002-01-08
AU768537B2 (en) 2003-12-18
PL195163B1 (pl) 2007-08-31
RU2246296C2 (ru) 2005-02-20
PL351259A1 (en) 2003-04-07
AU4111100A (en) 2000-10-23
EP1189620B1 (en) 2004-06-23
CA2366856A1 (en) 2000-10-12
PT1189620E (pt) 2004-10-29
IL145524A (en) 2006-12-31
JP2002541111A (ja) 2002-12-03
NO20014718L (no) 2001-09-28
HK1043544A1 (en) 2002-09-20
KR20010108435A (ko) 2001-12-07
NZ514290A (en) 2003-08-29
NO329420B1 (no) 2010-10-18
CA2366856C (en) 2006-05-16
SK13722001A3 (sk) 2002-02-05
CZ20013507A3 (cs) 2002-03-13
EP1189620A1 (en) 2002-03-27
ID30481A (id) 2001-12-13
DK1189620T3 (da) 2004-08-16
HU229455B1 (en) 2013-12-30
ZA200107781B (en) 2002-12-20
ATE269708T1 (de) 2004-07-15
CZ298573B6 (cs) 2007-11-14
SK286071B6 (sk) 2008-02-05
KR100666016B1 (ko) 2007-01-10
TWI280124B (en) 2007-05-01
MXPA01009919A (es) 2002-04-24
WO2000059512A1 (en) 2000-10-12
CN1155385C (zh) 2004-06-30
TR200102769T2 (tr) 2002-05-21
DE60011771D1 (de) 2004-07-29

Similar Documents

Publication Publication Date Title
DE60011771T2 (de) Formulierung enthaltend testosteonundecanoat und rizinusöl
DE69707669T2 (de) Orale pharmazeutische zusammensetzungen mit sexualhormonen
DE2624025C2 (https=)
DE69529060T2 (de) Verwendung eines lipophilen tensids in einer pharmazeutischen zusammensetzung
DE2508615C2 (https=)
DE3686936T2 (de) Am zielorgan wirkendes enterales abgabesystem.
DE68907858T2 (de) Arzneizubereitungen zur transdermalen Verabreichung von Wirkstoffen.
DE60114145T3 (de) Fulvestrant formulierung
DE69414840T2 (de) Akzeptabele pharmazeutische zusammensetzung enthaltend einen alkohol und einen hydrophalischen wirkstoff
DE60029602T2 (de) Lipasehemmer enthaltende dispersionsformulierungen
DE29824679U1 (de) Pharmazeutische Zusammensetzungen
DE60312193T2 (de) Pharmazeutische formulierung mit cyclosporin, propylenglycol-ester und nichtionischem tensid
KR20180123165A (ko) 스테로이드 호르몬 약제학적 조성물
DE4322826A1 (de) Pharmazeutisches Präparat
US20050287203A1 (en) Formulation comprising testosteron undecanoate and castor oil
DE3237814A1 (de) Wasserfreie emulsionen und verwendung derselben
KR20080009201A (ko) 소수성 약물의 약물전달시스템 및 이를 포함하는 조성물
DE69711267T2 (de) Cyclosporin enthaltende Weichkapselpräparate
DE3411225C2 (https=)
DE69525740T2 (de) Spezielle halofantrinhaltige Zusammensetzungen
DE3836862A1 (de) Mittel zur transdermalen applikation von steroidhormonen
EP0461290B1 (de) Flüssig befüllte Steckkapselpräparate
DE4244122C1 (de) Lyophilisierte, wirkstoffhaltige Emulsion zur intravenösen Applikation
CH643738A5 (en) Highly concentrated pharmaceutical steroid products
DE68902056T2 (de) 4-aroylimidazol-2-on enthaltende pharmazeutische zusammensetzung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: N.V. ORGANON, OSS, NL

R082 Change of representative

Ref document number: 1189620

Country of ref document: EP

Representative=s name: WUESTHOFF & WUESTHOFF PATENT- UND RECHTSANWAEL, DE